marketshareAI

ImmuPharma

IMMHealthcare
3.1283GBX
5.15%
Market Cap
13.03M
Volume
1.1M
30% of avg
P/E Ratio
-0.01
EPS (TTM)
-3.39
Beta
2.67
Day Range
2.8200p - 3.4900p
52 Week Range
0.8500p3.1283p7.4000p
3.1283p

Upcoming Events

01 September 2025
Phase II Clinical Trial Results for P140 in CIDP
High Impact Event
30 September 2025
Expiry of extended warrants in Incanthera
Q1 2026
Phase III Clinical Trial Results for P140 in SLE
High Impact Event
FY 2026
Incanthera projects revenues of £33m and increased profitability
High Impact Event
2030
Relevant therapy markets forecast to reach global sales of c.$360 billion
High Impact Event
IMM
NEUTRAL

ImmuPharma Extends Warrants in Incanthera to 2025

The biopharmaceutical company has agreed to extend the exercise period of warrants in Incanthera plc to September 2025.

IMM
NEUTRAL

ImmuPharma to Attend Bio-Europe Spring Conference in Milan

The biopharmaceutical company will be present at the upcoming Bio-Europe Spring conference in Milan, providing networking opportunities.

IMM
NEUTRAL

ImmuPharma Provides Update on P140 Mechanism of Action

The biopharmaceutical company has announced new findings that provide evidence for the unique mechanism of action of its P140 autoimmune technology platform.

IMM
NEUTRAL

ImmuPharma Announces Change in Major Shareholding

The biotechnology company has announced a change in major shareholding, with an institutional investor increasing their stake.

IMM
NEUTRAL

ImmuPharma Raises £2.91m in Oversubscribed Fundraise

The biopharmaceutical company has raised £2.91 million through an oversubscribed placing and subscription, with funds to be used for further investment in its autoimmune technology platform and general working capital.

IMM
GOOD

ImmuPharma Announces Breakthrough Autoimmune Research

The biopharmaceutical company announces groundbreaking progress in its autoimmune disease research, positioning it for potential partnerships and commercialization opportunities.

IMM
GOOD

ImmuPharma Announces Breakthrough Findings in Autoimmune Disease Research

The biopharmaceutical company has made breakthrough discoveries in its research on autoimmune disease mechanisms, which could lead to advancements in diagnostics and personalized treatments.

IMM
NEUTRAL

ImmuPharma to Attend Key Biotech Conferences in San Francisco

Biotech company ImmuPharma to attend key industry conferences in San Francisco.

IMM
NEUTRAL

ImmuPharma Appoints New Auditor

Routine administrative update for this specialty biopharmaceutical company

IMM
NEUTRAL

ImmuPharma Announces Change in Major Shareholding

The biopharmaceutical company announces a change in major shareholding, with Lanstead Capital Investors LP reducing its stake from 9.99% to 6.90%.